Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity

Sara Wahlin(Lund University), Karin Jirström(Lund University)
BMC Cancer
February 2, 2022
10.1186/s12885-021-09168-7
Cited by 6

Related Papers

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer
|Modern Pathology|2009|85
Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer
|British Journal of Cancer|2013|75
The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma
|Oncotarget|2017|62
Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival
|Frontiers in Oncology|2019|45
Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study
|Biomarker Research|2017|18